Applications of virus-specific T cell therapies post-BMT

Area of Science:

• Immunology
• Virology
• Oncology

Background:

• Hematopoietic stem cell transplantation (HSCT) is a standard treatment for primary immunodeficiencies and hematologic malignancies.
• Viral infections pose a significant threat post-HSCT due to immune deficiency, with limited options from conventional antiviral drugs.
• Adoptive immunotherapy using virus-specific T cells (VSTs) presents an alternative strategy.

Approach:

• This review examines methods for generating VSTs for clinical application.
• It summarizes clinical outcomes from studies using VST therapeutics.
• The review also discusses current challenges and future prospects in the field.

Key Points:

• VSTs have demonstrated safety and efficacy in Phase I-II trials for preventing and treating viral infections like CMV, EBV, BK virus, and adenovirus post-HSCT.
• This immunotherapy approach exhibits minimal toxicity and a low risk of graft-versus-host disease.
• VSTs overcome limitations associated with traditional antiviral pharmacotherapies, such as toxicity and drug resistance.

Conclusions:

• VSTs represent a viable and effective adoptive immunotherapy for managing viral infections in HSCT recipients.
• Further research and development are crucial to optimize VST generation and expand their clinical use.
• The field is advancing towards improved strategies for harnessing T cell immunity against post-transplant viral complications.